FDA Approves Genentech’s Vabysmo Prefilled Syringe (PFS) for Three Leading Causes of Vision Loss
FDA approves Genentech's Vabysmo Prefilled Syringe (PFS) for wet age-related macular degeneration (AMD), diabetic macular edema (DME), and macular edema following retinal vein occlusion (RVO), affecting nearly 3 million people in the U.S. Vabysmo PFS, a bispecific antibody, offers a ready-to-use format, enhancing treatment simplicity and effectiveness.
Highlighted Terms
Related News
FDA Approves Genentech’s Vabysmo Prefilled Syringe (PFS) for Three Leading Causes of Vision Loss
FDA approves Genentech's Vabysmo Prefilled Syringe (PFS) for wet age-related macular degeneration (AMD), diabetic macular edema (DME), and macular edema following retinal vein occlusion (RVO), affecting nearly 3 million people in the U.S. Vabysmo PFS, a bispecific antibody, offers a ready-to-use format, enhancing treatment simplicity and effectiveness.